The Czech Republic's State Institute for Drug Control has approved the Illuccix PSMA-PET imaging kit for adult patients with prostate cancer. The imaging agent, gallium-68 (68Ga) gozetotide injection, is now authorized for detecting PSMA-positive lesions in several clinical scenarios, including high-risk primary staging and suspected recurrent prostate cancer. This advancement aims to enhance diagnosis accuracy and treatment decision-making for patients. The approval is supported by findings from the phase 3 VISION trial, which demonstrated improved patient outcomes with the use of PSMA-targeted therapies. Illuccix will be distributed in the Czech Republic through THP Medical Products, contributing to the country’s leadership in adopting advanced diagnostic techniques.
Fri, 09 May 2025 16:23:03 GMT | OncLive